Our Journey and Mission
Our Experts
Join Our Journey
Almero Bourbon
Founder – Group CEO
He brings three+ decades of global executive leadership and expertise to Ænigma Biosciences as co-founder. Combining his deep experiential scientific knowledge, proven execution, drives the breakthrough innovations in bio-pharma technology. His diversification in AI-driven bioscience diagnostics coupled with bio-actives and phytochemistry expertise, primarily drove the revolutionizing of drug solubility and bioavailability challenges. This interdisciplinary approach with a particular depth in cannabinoids, terpenoids, flavonoids, and natural bio-actives combined with his systems approach enables the design and validation of synergistic formulations that directly address the industry’s most persistent challenge – 90% of pipeline drugs, plagued by poor solubility and absorption. The ability to integrate complex technologies into scalable solutions, architecting multi-channel commercialization strategies, successfully translate into cutting-edge scientific breakthroughs and market-ready innovations. This combination of scientific depth, systems thinking, and commercial acumen makes him a transformative leader at the intersection of nanotechnology, biosciences, and pharmaceutical innovation.
Prof. Pradeep Kumar
Key Opinion Leader
World-class scientific excellence as a Personal Professor of Pharmaceutics at Wits, with a PhD in Neural Science and Nano Delivery Systems. Established as a global leader in neuro-materials and bio-materials science, pharmaceutical sciences and drug delivery, nanomedicine and tissue engineering, and molecular pharmaceutics. Exceptional research credentials including over 350 published outputs with more than 14,000 citations (H-index: 52), earning him recognition in Stanford’s prestigious list of the top 2% of scientists worldwide for seven consecutive years (2020-2024)1.
Professor Kumar’s 15+ years of expertise in biomaterial design, tissue engineering, and nanomedicine has resulted in groundbreaking innovations across multiple therapeutic areas. As an inventor on 34 granted patents, his portfolio spans ultrafast dissolving matrices, resorbable wound dressings, anti-cancer targeting peptides, oral protein delivery systems, spinomimetic scaffolds, nerve conduits, thermogels, and vaginal tablets. His distinguished career has been recognized with numerous prestigious awards, including the 2021 Vice-Chancellor’s Innovation Award, appointment as an IAP/World Health Summit’s Physician Leader under WHO aegis, the WHC Great Leap Forward Entrepreneurial Academic Award, and his current second term on the ORCID Researcher Advisory Council.
Dr. Priyamvada Pradeep
Lead Formulation Scientist
Pharmacist with Masters of Science in Medicinal Chemistry and PhD in Organic Chemistry Her research encompasses: Synthetic Organic Chemistry: Multistep synthesis of organic molecules, Medicinal Chemistry: Investigation of therapeutic molecules and reaction mechanisms, In Silico Screening: Generation of therapeutic molecules through computational methods, Biomaterials Synthesis: Advanced material design for pharmaceutical applications, Drug Delivery Systems: Development of novel delivery platforms. She has extensive experience in preformulation /formulation development.
Waldemar Paclawski
COO Europe & Market Strategist, Ænigma Biosciences
Waldemar Pacławski is an investment executive and strategist with over three decades of experience in private equity, M&A, and family office advisory across Europe and Asia. A London School of Economics graduate and Harvard BS resident alumnus, he has led transactions exceeding €700M and advised on cross-border restructurings and IPOs. As Ænigma’s COO for Europe, he oversees finance, partnerships, and market strategy, bringing a strong European perspective to biotech growth, governance, and capital deployment.
